ADXS11-001 immunotherapy targeting HPV-E7: Final results from a phase 2 study in Indian women with recurrent cervical cancer.

Basu, Partha; Mehta, Ajay; Jain, Minish; Gupta, Sudeep; Nagarkar, Rajnish; Kumar, Vijay; Premkumar, Sumana; Neve, Rakesh; John, Subhashini; Petit, Robert G.

doi:10.1200/jco.2014.32.15_suppl.5610

Cited by 24 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall 12-and 18-month survival rates were 36 and 28% with overall response rate of 11% (six complete and six partial). Of note, vaccination was well tolerated with only 2% of grade 3 adverse events [133]. On this basis a randomized Phase III study is planned.…”

Section: Immunotherapeutic Agents For CCmentioning

confidence: 98%

Emerging drugs for the treatment of cervical cancer

Serrano-Olvera

Cetina

Coronel

et al. 2015

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

Concurrent cisplatin with radiation and lately, gemcitabine-cisplatin chemoradiation has resulted in small but significant improvements in the treatment of locally advanced and high-risk early-stage patients. So far, only antiangiogenic therapy with bevacizumab added to cisplatin chemoradiation has demonstrated safety and encouraging results in a Phase II study. In advanced disease, cisplatin doublets yield median survival rates not exceeding 14 months. The first Phase III study of bevacizumab, added to standard chemotherapy cisplatin- or non-cisplatin-containing doublet, has shown significant increase in both overall survival and progression-free survival. Further studies are needed before bevacizumab plus chemotherapy can be considered the standard of care for advanced disease. The characterization of the mutational landscape of CC and developments of novel targeted therapies may result in more effective and individualized treatments for CC. The potential efficacy of knocking down the key alterations in CC, E6 and E7 human papilloma virus oncoproteins must not be overlooked.

show abstract

Section: Immunotherapeutic Agents For CCmentioning

confidence: 98%

Emerging drugs for the treatment of cervical cancer

Serrano-Olvera

Cetina

Coronel

et al. 2015

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

show abstract

“…71 A Listeria-based vaccine, ADXS11-001, demonstrated an 11% response rate in a phase 2 investigation among patients with recurrent or refractory cervical cancer. 72 OPC Treatment for OPC is the same regardless of HPV status or p16 positivity, despite improved outcomes in HPVpositive OPC. Patients with early stage OPC can be treated with either primary surgery and/or definitive RT.…”

Section: Cervical Cancermentioning

confidence: 99%

Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases

Berman

Schiller

2017

Cancer

329

261

View full text Add to dashboard Cite

Human papillomavirus (HPV) causes greater than 5% of cancers worldwide, including all cervical cancers and an alarmingly increasing proportion of oropharyngeal cancers (OPCs). Despite markedly reduced cervical cancer incidence in industrialized nations with organized screening programs, cervical cancer remains the second most common cause of death from cancer in women worldwide, as developing countries lack resources for universal, high-quality screening. In the United States, HPV-related OPC is only 1 of 5 cancers with a rising incidence since 1975 and now has taken over the cervix as the most common site of HPV-related cancer. Similar trends follow throughout North America and Europe. The need for early detection and prevention is paramount. Despite the common etiologic role of HPV in the development of cervical cancer and HPV-associated OPC, great disparity exists between incidence, screening modalities (or lack thereof), treatment, and prevention in these 2 very distinct cohorts. These differences in cervical cancer and HPV-associated OPC and their impact are discussed here. Cancer 2017;123:2219-2229. © 2017 American Cancer Society.

show abstract

“…Specifically, a live attenuated Listeria monocytogenes (Lm) vaccine containing an HPV-16-E7 fusion protein was initially used in a phase II study by a group in India [34]. In this study, 110 patients with recurrent squamous cell carcinoma (SCC) of the cervix were randomized to three doses of the vaccine alone versus four doses of the vaccine with concurrent cisplatin chemotherapy.…”

Section: Cervixmentioning

confidence: 99%

Immunotherapy in Gynecologic Cancers: Are We There Yet?

Pakish

Jazaeri

2017

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Opinion statement Immune-targeted therapies have demonstrated durable responses in many tumor types with limited treatment options and poor overall prognosis. This has led to enthusiasm for expanding such therapies to other tumor types including gynecologic malignancies. The use of immunotherapy in gynecologic malignancies is in the early stages and is an active area of ongoing clinical research. Both cancer vaccines and immune checkpoint inhibitor therapy continue to be extensively studied in gynecologic malignancies. Immune checkpoint inhibitors, in particular, hold promising potential in specific subsets of endometrial cancer that express microsatellite instability. The key to successful treatment with immunotherapy involves identification of the subgroup of patients that will derive benefit. The number of ongoing trials in cervical, ovarian, and endometrial cancer will help to recognize these patients and make treatment more directed. Additionally, a number of studies are combining immunotherapy with standard treatment options and will help to determine combinations that will enhance responses to standard therapy. Overall, there is much enthusiasm for immunotherapy approaches in gynecologic malignancies. However, the emerging data shows that with the exception of microsatellite unstable tumors, the use of single-agent immune checkpoint inhibitors is associated with response rates of 10– 15%. More effective and likely combinatorial approaches are needed and will be informed by the findings of ongoing trials.

show abstract

ADXS11-001 immunotherapy targeting HPV-E7: Final results from a phase 2 study in Indian women with recurrent cervical cancer.

Cited by 24 publications

References 0 publications

Emerging drugs for the treatment of cervical cancer

Emerging drugs for the treatment of cervical cancer

Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases

Immunotherapy in Gynecologic Cancers: Are We There Yet?

Contact Info

Product

Resources

About